At a glance
ClinicalIndex Comparison RecordN/ACompleted· 60 enrolled
Drug / intervention
molecular breast imaging (Discovery)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Assessment of Molecular Breast Imaging (MBI) in Distinguishing Benign From Malignant Breast Disease.
In Brief
A clinical study evaluating molecular breast imaging (Discovery) for Breast Abnormalities. Completed, enrolled 60 participants across 1 site.
Detailed Summary
The primary hypothesis of this project is that using molecular breast imaging (MBI) in evaluating women with equivocal mammographic or sonographic findings will demonstrate high specificity in distinguishing benign from malignant breast disease and, as a result, decrease the number of biopsies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Abnormalities
CountriesUnited States
CollaboratorsGE Healthcare
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2012
First PostedSep 2012
Primary CompletionSep 2014
TodayJul 2026
First PostedSep 19, 2012
Enrollment StartSep 1, 2012
Primary CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 13.8 years ago
Interventions
molecular breast imaging (Discovery)device